| 1564 |
National Cancer Institute |
Html |
en |
Laryngeal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of laryngeal cancer. |
| treatment | 0.456448 |
| cancer treatment | 0.208981 |
| vocal cords | 0.463035 |
| Laryngeal Cancer Treatment | 0.208444 |
| NCI-supported cancer | 0.201905 |
| cancer cells | 0.32099 |
| stage laryngeal cancer | 0.221553 |
| body | 0.20156 |
| chemotherapy | 0.227934 |
| PDQ cancer information | 0.235798 |
| larynx | 0.286996 |
| clinical trial search | 0.245354 |
| Hyperfractionated radiation therapy | 0.214818 |
| laryngeal cancer spreads | 0.200731 |
| National Cancer Institute | 0.254821 |
| laryngeal cancer | 0.644668 |
|
| clinical trials | 0.596105 |
| metastatic laryngeal cancer | 0.202273 |
| cancer information summary | 0.213869 |
| clinical trial | 0.439358 |
| Recurrent laryngeal cancer | 0.222324 |
| new treatment | 0.207333 |
| patients | 0.231814 |
| neck | 0.206846 |
| original tumor | 0.252057 |
| cancer clinical trials | 0.262761 |
| stage | 0.247854 |
| lymph nodes | 0.238789 |
| lymph node | 0.41143 |
| radiation therapy | 0.83207 |
| cancer | 0.992267 |
|
CLICK HERE |
| 1645 |
National Cancer Institute |
Html |
en |
Gonzalez Regimen (PDQ®)–Patient Version |
Expert-reviewed information summary about the Gonzalez regimen as a treatment for people with cancer.
Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| metabolic type | 0.635617 |
| cancer prevention | 0.611486 |
| NCI Best Case | 0.598906 |
| mainstream medical community | 0.586423 |
| scientific methods | 0.589903 |
| PDQ cancer information | 0.678785 |
| Cancer Complementary | 0.593506 |
| pancreatic cancer | 0.652631 |
| CAM therapies | 0.667976 |
| treatment clinical trials | 0.608837 |
| National Cancer Institute | 0.779385 |
| clinical trials | 0.720584 |
| important body processes | 0.609904 |
| alternative medicine | 0.70039 |
| NIH National Library | 0.589764 |
| cancer information summary | 0.665644 |
| alternative cancer therapies | 0.639162 |
| advanced pancreatic cancer | 0.627348 |
| clinical trial | 0.631473 |
| National Center | 0.597871 |
| PubMed bibliographic database | 0.587523 |
| new treatment | 0.61493 |
| breast cancer prevention | 0.609001 |
| certain scientific questions | 0.59076 |
|
| patients | 0.729305 |
| cancer patients | 0.591541 |
| 7-year clinical study | 0.608255 |
| latest published information | 0.596234 |
| Gonzalez regimen | 0.972553 |
| easy-to-use search tool | 0.586572 |
| Integrative Health | 0.595025 |
| NCI PDQ cancer | 0.643516 |
| cancer information database | 0.621215 |
| Health care professionals | 0.588662 |
| alternative therapies | 0.621194 |
| purely alternative approaches | 0.593886 |
| complementary therapies | 0.587662 |
| Gonzalez regimen group | 0.693146 |
| New York physician | 0.598832 |
| health professional versions | 0.595534 |
| prospective studies | 0.59024 |
| cancer | 0.820591 |
| research studies | 0.596285 |
| Nicholas Gonzalez | 0.593123 |
| conventional treatments | 0.632214 |
| Dr. Gonzalez | 0.59152 |
| small number | 0.597616 |
|
CLICK HERE |
| 1665 |
National Cancer Institute |
Html |
null |
Last Days of Life (PDQ®)–Patient Version |
Expert-reviewed information summary about care during the last days to last hours of life, including common symptoms, ethical dilemmas that may arise, and the role of the oncologist in caring for patients and their families during this time. |
|
|
CLICK HERE |
| 1672 |
National Cancer Institute |
Html |
en |
Pediatric Supportive Care (PDQ®)–Patient Version |
Expert-reviewed information summary about the unique issues that arise for children during their treatment for cancer, after the completion of treatment, and as adult survivors of cancer. |
| cancer treatment | 0.673763 |
| mental health | 0.594918 |
| childhood cancer survivors | 0.660763 |
| PDQ cancer information | 0.632459 |
| health care team | 0.597981 |
| childhood cancer patients | 0.499693 |
| children | 0.602725 |
| cancer treatment doctors | 0.562323 |
| different age groups | 0.509717 |
| clinical trials | 0.536936 |
| mental health problems | 0.576551 |
| early treatment | 0.493575 |
| cancer information summary | 0.576245 |
| regular mental health | 0.520572 |
| NCI PDQ cancer | 0.534007 |
| effects | 0.524597 |
| supportive care | 0.660168 |
| young adults | 0.515271 |
| childhood cancer | 0.678101 |
| late effects | 0.509447 |
| health care support | 0.494832 |
| care | 0.735246 |
| child | 0.686462 |
| end-of-life care | 0.567481 |
| parents | 0.506649 |
|
| cancer treatments | 0.501032 |
| treatment | 0.871904 |
| mental health specialist | 0.520368 |
| cancer experience | 0.49362 |
| mental health check-ups | 0.521913 |
| palliative care | 0.553378 |
| Cancer Information Service | 0.502777 |
| Follow-up cancer care | 0.566023 |
| child end-of-life care | 0.503834 |
| National Cancer Institute | 0.574409 |
| certain childhood cancer | 0.500961 |
| health care | 0.604883 |
| Palliative Care Editorial | 0.521086 |
| cancer treatment doctor | 0.57306 |
| new treatment | 0.522928 |
| Cancer Care page | 0.512127 |
| Care Editorial Board | 0.522941 |
| PDQ summary | 0.567319 |
| cancer information summaries | 0.506731 |
| cancer patient | 0.507833 |
| comprehensive cancer information | 0.506663 |
| PDQ Supportive Care | 0.533813 |
| cancer | 0.997123 |
| follow-up care | 0.516276 |
|
CLICK HERE |
| 1689 |
National Cancer Institute |
Html |
en |
Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood central nervous system germ cell tumors. |
| craniospinal irradiation | 0.568926 |
| intracranial germinoma | 0.542559 |
| survival rates | 0.505415 |
| excellent survival rates | 0.497286 |
| endodermal sinus tumor | 0.492396 |
| germ cell tumor | 0.543477 |
| chemotherapy | 0.510034 |
| reduced-volume radiation therapy | 0.492394 |
| ifosfamide based chemotherapy | 0.484152 |
| Tumors Treatment Overview | 0.506029 |
| primordial germ cells | 0.489907 |
| focal radiation therapy | 0.518434 |
| pure germinomas | 0.484971 |
| Radiat Oncol Biol | 0.492523 |
| tumor markers | 0.56413 |
| radiation therapy doses | 0.490668 |
| CNS germ cell | 0.55586 |
| tumor markers AFP | 0.505621 |
| cerebrospinal tumor markers. | 0.502663 |
| conventional whole-brain irradiation | 0.482504 |
| whole-ventricular radiation therapy | 0.492409 |
| CSF AFP levels | 0.509387 |
| nongerminomatous germ cell | 0.513106 |
| cell tumor study | 0.490435 |
| yolk sac tumor | 0.491117 |
|
| germ cell theory | 0.506108 |
| common solid tumor | 0.502347 |
| germinomatous germ cell | 0.4915 |
| primary chemotherapy | 0.487412 |
| radiation therapy | 0.751812 |
| et al. | 0.485468 |
| Low-dose craniospinal irradiation | 0.484891 |
| CNS GCTs | 0.523584 |
| whole-ventricle radiation therapy | 0.491449 |
| SIOP CNS GCT | 0.490345 |
| brain tumor treatment | 0.516207 |
| primary brain tumors | 0.544753 |
| neoadjuvant chemotherapy results | 0.491554 |
| Pediatr Blood Cancer | 0.568832 |
| response-based radiation therapy | 0.486149 |
| radiation treatment volume | 0.488339 |
| boost radiation therapy | 0.486976 |
| nervous system tumors | 0.483298 |
| Brain Tumor Study | 0.49693 |
| Oncol Biol Phys | 0.49429 |
| specific chemotherapy regimen | 0.484857 |
| intracranial germ cell | 0.58985 |
| germ cell tumors | 0.911962 |
| radiation therapy fields | 0.485192 |
|
CLICK HERE |
| 1970 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de paratiroides (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de paratiroides. |
| glándula tiroides | 0.438865 |
| Más sed | 0.410088 |
| siguientes procedimientos | 0.457489 |
| contraste circula | 0.409886 |
| glándula hiperactiva | 0.421803 |
| vÃa oral | 0.406242 |
| rayos x | 0.425707 |
| pequeñas marcas | 0.406116 |
| National Cancer Institute | 0.40574 |
| siguientes riesgos | 0.40413 |
| endocrina múltiple tipo | 0.418977 |
| Instituto Nacional | 0.410629 |
| malla ayuda | 0.405988 |
|
| hormona paratiroidea | 0.66472 |
| PDQ Tratamiento | 0.41212 |
| cabo pruebas | 0.412201 |
| glándulas paratiroides | 0.84566 |
| cuál glándula paratiroides | 0.475528 |
| Physician Data Query | 0.422464 |
| glándula paratiroides | 0.975564 |
| glándula paratiroides hiperactiva | 0.533736 |
| HPT ayuda | 0.413459 |
| toma imágenes | 0.439925 |
| siguientes pruebas | 0.41438 |
| largo tiempo | 0.406983 |
| siguientes trastornos | 0.411735 |
|
CLICK HERE |
| 2115 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de hígado (hepatocelular) (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer hepatocelular y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| chronic hepatitis b | 0.391786 |
| chronic hepatitis c | 0.392121 |
| available online | 0.329517 |
| American Cancer Society | 0.362594 |
| tt virus dna | 0.321147 |
| largo plazo | 0.314356 |
| with hepatocellular carcinoma | 0.362577 |
| hepatitis e | 0.456465 |
| CHC agudo | 0.334135 |
| denominación hepatitis no-A | 0.402257 |
| hepatocellular carcinoma | 0.818192 |
| Concurrent hepatitis | 0.385001 |
| Instituto Nacional | 0.321684 |
| Qidong hepatitis | 0.385791 |
| patients with chronic | 0.340288 |
| hÃgado llamada cirrosis | 0.31992 |
| hepatitis nanb | 0.397414 |
| risk factors | 0.334046 |
| hepatitis b | 0.815878 |
| hepatitis c | 0.64216 |
| Estados Unidos | 0.516836 |
| virus hepáticos forma | 0.324783 |
| Universal hepatitis | 0.404867 |
| Spanish patients with | 0.316748 |
| PDQ Prevención | 0.319178 |
|
| patients with | 0.420437 |
| carcinoma among patients | 0.322468 |
| SEER Cancer Statistics | 0.314302 |
| Rizzetto M | 0.316034 |
| Infect Dis | 0.316615 |
| virus carriers with | 0.326772 |
| natural history | 0.314507 |
| Ningún virus | 0.321223 |
| hepatocelular factores causales | 0.320088 |
| Viral Hepatitis FAQs | 0.396943 |
| National Cancer Institute | 0.335176 |
| La hepatitis | 0.94804 |
| Chang MH | 0.316907 |
| viral hepatitis | 0.515061 |
| Yuan JM | 0.316452 |
| GB virus | 0.317604 |
| correlate with expression | 0.314623 |
| Long-term phlebotomy with | 0.314798 |
| Liver Int | 0.354023 |
| Hepatocellular carcinoma without | 0.326846 |
| chronic hepatitis | 0.450334 |
| hepatitis aguda | 0.53174 |
| hepatitis tipos | 0.394509 |
| virus rna | 0.317794 |
|
CLICK HERE |
| 2974 |
National Cancer Institute |
Video |
en |
Challenge: Fitting fitness into your busy schedule |
Life can get really hectic sometimes. Between work, family and other obligations, it's hard to find time to exercise. But before you say you don't have time to exercise each day, consider this: even a little bit of exercise is better than no exercise at all! |
| little bit | 0.820288 |
| fitness | 0.392435 |
| work | 0.370295 |
| obligations | 0.461065 |
|
| Life | 0.388039 |
| exercise | 0.667358 |
| time | 0.674488 |
| family | 0.369813 |
|
CLICK HERE |
| 3570 |
National Cancer Institute |
Html |
en |
The NCI Outstanding Investigator Award (R35) |
The NCI Outstanding Investigator Award (OIA) supports investigators with outstanding records of productivity in cancer research by providing extended funding stability and encouraging investigators to continue or embark on projects of unusual potential in cancer research. |
| direct costs | 0.516422 |
| projects | 0.339999 |
| person months effort | 0.510514 |
| OIA | 0.56501 |
| greater risks | 0.517599 |
| Institution | 0.338577 |
| outstanding productivity | 0.586579 |
| cancer research | 0.764353 |
| funded investigators | 0.583615 |
|
| Award | 0.340824 |
| NCI Outstanding Investigator | 0.903247 |
| outstanding records | 0.61157 |
| recipient | 0.352813 |
| Principal Investigator | 0.547103 |
| PI | 0.388963 |
| substantial time | 0.526242 |
| NCI grant | 0.541618 |
| salary support | 0.509963 |
|
CLICK HERE |
| 17242 |
National Cancer Institute |
Html |
en |
National Cryo-Electron Microscopy Facility Team Members |
The National Cryo-Electron Microscopy Facility team is responsible for the operational activities of NCEF. Find team member bios and a list of NCEF working group members. |
| strategic oversight | 0.549362 |
| Lab Advisory Committee | 0.88433 |
| Frederick National Lab | 0.883241 |
| NCEF Senior Microscopist | 0.757617 |
| Molecular Virology | 0.5561 |
| government contract projects | 0.639164 |
| cancer researchers. | 0.551348 |
| Piermaria J. Oddone | 0.648956 |
| Thomas Edwards | 0.534246 |
| cryo-EM laboratories | 0.7289 |
| Grant J. Jensen | 0.61562 |
| advisory committee members | 0.653176 |
| research expertise | 0.57237 |
| PMP certification | 0.536505 |
| structural biology | 0.656766 |
| Advanced Computer Studies | 0.527736 |
| L. Mario Amzel | 0.617619 |
| NCEF Scientific Project | 0.683141 |
| Biophysics Section | 0.560804 |
| Stephen C. Harrison | 0.611643 |
| structural studies | 0.552951 |
| resolution cryo-electron microscopy | 0.682528 |
| structural biology communities | 0.646732 |
| academic research | 0.551259 |
| Hopkins University School | 0.630222 |
|
| Steven J. Ludtke | 0.641874 |
| cryo-EM services | 0.763943 |
| Senior Investigator | 0.530394 |
| Physical Biochemistry | 0.552108 |
| Infectious Disease research | 0.655231 |
| Sriram Subramaniam | 0.554662 |
| Angela M. Gronenborn | 0.615627 |
| Ph.D | 0.61505 |
| Hong Zhou | 0.531963 |
| core team | 0.649969 |
| structural analysis | 0.55203 |
| Ulrich Baxa | 0.572356 |
| Edward H. Egelman | 0.618207 |
| Cancer Research | 0.549211 |
| NCEF Microscopist | 0.616796 |
| National Lab Advisory | 0.882693 |
| adjunct faculty appointments | 0.637399 |
| strong background | 0.529367 |
| Cell Biology | 0.534261 |
| Project Management | 0.649065 |
| National Cryo-EM Facility | 0.904008 |
| Helen Wang | 0.529981 |
| single particle cryo-EM | 0.833864 |
| electron tomography | 0.5462 |
|
CLICK HERE |